The therapeutic strategy for obesity-associated Mets and T2DM - Hsieh, Po-Shiuan;Lu, Chieh-Hua
16,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
payback
8 °P sammeln
  • Broschiertes Buch

The prevalence of obesity-associated adipose tissue inflammation with metabolic syndrome and T2DM are increasing. The current guidelines recommend the use of metformin-based combination therapy for patients with T2DM. The therapeutic strategy for obesity-associated metabolic syndrome and T2DM, may require the inclusion of anti-inflammatory properties through appropriate drugs. We find an additional effect of metformin and celecoxib that represents a potential novel and powerful new strategy on obesity-associated lipid dysregulation and adipose tissue inflammation.

Andere Kunden interessierten sich auch für
Produktbeschreibung
The prevalence of obesity-associated adipose tissue inflammation with metabolic syndrome and T2DM are increasing. The current guidelines recommend the use of metformin-based combination therapy for patients with T2DM. The therapeutic strategy for obesity-associated metabolic syndrome and T2DM, may require the inclusion of anti-inflammatory properties through appropriate drugs. We find an additional effect of metformin and celecoxib that represents a potential novel and powerful new strategy on obesity-associated lipid dysregulation and adipose tissue inflammation.
Autorenporträt
Dr. Po-Shiuan Hsieh (MD, PhD) is currently the director of Institute of Preventive Medicine of National Defense Medical Center (NDMC), Taipei, Taiwan. Also, he is Professor at Physiology institute of NDMC. In addition, he serves as the Editor-in-Chief of Journal of Medical Science and Chinese Journal of Physiology (SCI).